A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy
- PMID: 22199105
- PMCID: PMC3249964
- DOI: 10.4103/0971-5916.90991
A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy
Abstract
Background & objectives: Angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) have been used to normalize the blood pressure and the dipping pattern in patients with type 1 diabetes mellitus (T1DM) and nephropathy. However, there are no data on the effect of the dual blockade on the dipping pattern in these subjects. We therefore, carried out this study to evaluate the effect of administrating an ACEI followed by ARB in the optimum doses in T1DM patients with nephropathy on 24 h blood pressure (BP) profile and nocturnal dipping pattern.
Methods: An open label interventional pilot study was done during a one year period involving 30 consecutive patients who were treated with telmisartan 80 mg (0800-1000 h) for eight weeks followed by addition of ramipril 10 mg (1200-1400 h) for the next eight weeks. Ambulatory BP, dipping pattern and albumin excretion rate were studied after each phase. Twenty patients were hypertensive and 10 patients had macro- and 20 patients had microalbuminuria.
Results: Telmisartan produced a fall in the clinic BP by 4/1.3 mm Hg (P<0.05 and P<0.362, respectively), 2/1.9 mm Hg in the mean 24 h BP, 1.4/1.1 mm Hg in the day BP and 3.7/3 mm Hg in the trough BP. Addition of ramipril to telmisartan produced a further reduction of 6.3/5.9 mm Hg in the clinic BP (P<0.001 for both), 4.3/4.2 mm Hg in the mean 24 h BP (P<0.01 and P<0.0001, respectively), 5.8/3.9 mm Hg in the day BP (P<0.01 for both), 4.2/2.5 mm Hg in the trough BP, with a reduction of clinic SBP and DBP of 10.3/7.2 mm Hg from the baseline. Telmisartan restored normal systolic dipping pattern in 33.3 per cent of the nondippers (P<0.01) but addition of ramipril was not complimentary. Hyperkalamia (>5.5 mmol/l) was observed only in 2 patients towards the end of the study.
Interpretation & conclusions: The dual blockade with telmisartan and ramipril had complimentary effect on lowering of the BP, however, similar beneficial effect on the nocturnal dipping was not observed. Further studies with large number of subjects with longer duration of follow-up are required to validate these observations.
Similar articles
-
A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.Am J Hypertens. 2006 Jan;19(1):104-12. doi: 10.1016/j.amjhyper.2005.10.001. Am J Hypertens. 2006. PMID: 16461201 Clinical Trial.
-
A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.Indian J Pharmacol. 2015 Mar-Apr;47(2):148-52. doi: 10.4103/0253-7613.153420. Indian J Pharmacol. 2015. PMID: 25878372 Free PMC article.
-
Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.Indian J Med Res. 2010 Jul;132:42-7. Indian J Med Res. 2010. PMID: 20693588
-
Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.Vasc Health Risk Manag. 2014 Apr 5;10:189-200. doi: 10.2147/VHRM.S59429. eCollection 2014. Vasc Health Risk Manag. 2014. PMID: 24741317 Free PMC article. Review.
-
Renal protection in diabetes: lessons from ONTARGET.Cardiovasc Diabetol. 2010 Oct 1;9:60. doi: 10.1186/1475-2840-9-60. Cardiovasc Diabetol. 2010. PMID: 20920303 Free PMC article. Review.
Cited by
-
Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis.Diabetes Ther. 2019 Feb;10(1):229-243. doi: 10.1007/s13300-018-0551-9. Epub 2019 Jan 7. Diabetes Ther. 2019. PMID: 30617943 Free PMC article.
References
-
- Sally M, Marshall . Clinical features and management of diabetic nephropathy. In: Pickup JC, Williams G, editors. Text book of diabetes. 3rd ed. Oxford, UK: Blackwell Publishing Co.; 2003. pp. 53.1–22.
-
- Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, editor. Brenner and rectors. The kidney. 6th ed. Saunders; 2000. pp. 1777–818.
-
- Standards of medical care in diabetes. American Diabetes Association. Diabetes Care. 2008;l31(s1):S12–54. - PubMed
-
- Hansen TN, Jeppesen J, Rasmusen S, Ibsen H, Torp-Petersen C. Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens. 2006;19:243–50. - PubMed
-
- Kikuya M, Hansen TN, Thijs L, Bjo¨ rklund- Bodegard K, Kuznetsova T, Ohkubo T, et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation. 2007;115:2145–52. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical